

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Complete If Known

<b>Application Number</b>	09/709,170
<b>Filing Date</b>	November 10, 2000
<b>First Named Inventor</b>	Warrell, Raymond
<b>Art Unit</b>	1635
<b>Examiner Name</b>	Gibbs, Terra C.

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket No: GEN0008-01US
-------	---	----	---	----------------------------------

**US PATENT DOCUMENTS**

Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate
--------------------	---------	-----------------	------------------	---	----------------------------

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
---------------------	---------	-------------------------	------------------	---	----------------

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		"USPTO Final Office Action mailed 10/14/08 for U.S. Application Serial No. 10/738,867 filed 12/16/03", 23 pp.	
		"International Search Report for PCT/US03/41433", (01/11/2005), 3 pp.	
		CHESON, "Hematologic Malignancies: New Development and Future Treatments", <i>Seminars in Oncology</i> Vol. 29, No. 4 (supplement 13), (2002 Aug 29), 33-45	
		KOSMIDIS, et al., "Oxiplatin/Etoposide Versus Carboplatin/Etoposide Chemotherapy and Irradiation in Small Cell Lung Cancer: A Randomized Phase III Study", <i>Seminars in Oncology</i> , Vol. 2, No. 3 (supplement 6), (1994 Jun.), 23-30	
		LOPES, et al., "Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2 Antisense Oligonucleotide G3139 Combined with Free and Liposomal Doxorubicin", <i>Clinical Cancer Research</i> , Vol. 6, (2000 Jul.), 2891-2902	
		MIYAKE, et al., "Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer with the Use of Antisense Bcl-2 Oligodeoxynucleotides", <i>Journal of the National Cancer Institute</i> , Vol. 92, No. 1, (2005 Jan. 5), 34-41	
		TOLCHER, "Preliminary Phase I Results of G3139 (bcl-2 Antisense Oligonucleotide) Therapy in Combination with Docetaxel in Hormone-Refractory Prostate Cancer", <i>Seminars in Oncology</i> , Vol. 28, No. 4 (supplement 15), (2001 Aug.), 67-70	
		JANSEN, B. et al., "Chemosensitisation of malignant melanoma by BCL2 antisense therapy", <i>Early Report: The Lancet</i> , Volume 356, (Nov. 18, 2000), 1728-1733	
		MCLAUGHLIN, P. et al., "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program", <i>J. of Clinical Oncology</i> , Vol. 16:8, (August 1998), 2825-2833	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Complete If Known

<b>Application Number</b>	09/709,170
<b>Filing Date</b>	November 10, 2000
<b>First Named Inventor</b>	Warrell, Raymond
<b>Art Unit</b>	1635
<b>Examiner Name</b>	Gibbs, Terra C.

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Attorney Docket No: GEN0008-01US

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		CHI, KIM et al., "A Phase I Trial of an Antisense Oligonucleotide to BCL-2 (G3139, Genta) and Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer (HRPC)", <u>Meeting: 2000 ASCO Annual Meeting, Abs. No.: 1299, 1 pp.</u>	
		CHI, KIM et al., "A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer", <u>Clinical Cancer Research, vol. 7, (December 2001), 3920-3927</u>	
		BANERJEE, DEBABRATA, "Genasense Genta Inc. Current Opinion In Investigational Drugs 2001 2(4) (2001), 574-580	
		CHEN, HELEN et al., "A Phase I Study of BCL-2 Antisense G3139 (GENTA) and Weekly Docetaxel in Patients with Advanced Breast Cancer and Other Solid Tumors", <u>Meeting: 2000 ASCO Annual Meeting, Abs. No.: 692, 1 pp.</u>	
		SCHER, HOWARD et al., "A Phase I Trial of G3139 (Genta, Inc.), a BCL-2 Antisense Drug by Continuous Infusion (CI) as a Single Agent and with Weekly Taxol (T)", <u>Meeting: 2000 ASCO Annual Meeting, Abs. No.: 774, 1</u>	
		"International Preliminary Examination Report for PCT/US03/41433 (Sep. 13, 2005) 5 pp.",	
		IYER, et al., "Clinical pharmacology of camptothecins", <u>Cancer Chemother Pharmacol. (1998), 42 (Suppl): S31-S-43</u>	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 † Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.